We believe that the definition of HER2-low BC will continue to evolve based on the development of new drugs, the results of future clinical trials, the development of more sensitive and reliable testing methods, and our understanding of HER2-expressing BCs. The gene discussed is ERBB2; the disease is breast cancer.